In 1963 and 1964, Garvan and Gunner1) reported that large volume parenteral solutions often contained a variety of foreign particulate matter in alarmingly large quantities, and they claimed that the use of a rubber closure gave rise to specific contaminants. Further, a Symposium on Safety of Large Volume Parenteral Solutions sponsored by the FDA2) in 1966 emphasized the importance of foreign particulate matter present in injectable solutions. Since then, an increasing number of reports have described the presence of such particulate matter and the consequent safety problem.3-12) A requirement that certain small volume injections meet particulate matter standards became official in USP on January 1, 1986. A recent report9) states that barium sulfate was found in injectable solutions sealed in glass ampules when sulfate or an oxidant such as sodium sulfite is contained in the products. This paper deals with the formation of barium sulfate crystals as a reaction product between aminoglycoside antibiotics and glass ampules. 
